# Intracoronary Optical Coherence Tomography: A Comprehensive Review 

# Clinical and Research Applications 

Hiram G. Bezerra, MD, PHD,* Marco A. Costa, MD, PhD, ${ }^{*}$ Giulio Guagliumi, MD, $\ddagger$ Andrew M. Rollins, PhD, $\dagger$ Daniel I. Simon, MD*

Cleveland, Ohio; and Bergamo, Italy


#### Abstract

Cardiovascular optical coherence tomography (OCT) is a catheter-based invasive imaging system. Using light rather than ultrasound, OCT produces high-resolution in vivo images of coronary arteries and deployed stents. This comprehensive review will assist practicing interventional cardiologists in understanding the technical aspects of OCT based upon the physics of light and will also highlight the emerging research and clinical applications of OCT. Semi-automated imaging analyses of OCT systems permit accurate measurements of luminal architecture and provide insights regarding stent apposition, overlap, neointimal thickening, and, in the case of bioabsorbable stents, information regarding the time course of stent dissolution. The advantages and limitations of this new imaging modality will be discussed with emphasis on key physical and technical aspects of intracoronary image acquisition, current applications, definitions, pitfalls, and future directions. (J Am Coll Cardiol Intv 2009;2:1035-46)


 © 2009 by the American College of Cardiology Foundation
## Concepts in Biophotonics

The fundamental principles of optical coherence tomography (OCT) evolved from optical 1-dimensional low-coherence reflectometry, which uses a Michelson interferometer and a broadband light source. In 1991, the addition of transverse scanning (B-scan), enabled 2-dimensional imaging of the retina (1). This technique was named OCT by James Fujimoto and rapidly expanded to numerous biomedical and clinical applications. Intravascular OCT requires a single fiberoptic wire that both

[^0]emits light and records the reflection while simultaneously rotating and being pulled back along the artery.

The coronary OCT light source uses a bandwidth in the near-infrared spectrum with central wavelengths ranging from 1,250 to $1,350 \mathrm{~nm}$. Although longer wavelengths provide deeper tissue penetration, the optimal choice of wavelength in an arterial vessel is also defined by tissue absorption characteristics and the refractive index of the interface between the catheter and vessel wall. Current intravascular OCT systems use a central wavelength of approximately $1,300 \mathrm{~nm}$. Using this wavelength the tissue penetration is limited to 1 to 3 mm as compared with 4 to 8 mm achieved by intravascular ultrasound (IVUS), with the exception of calcified lesions in which sound has a limited penetration.

The image is formed by the backscattering of light from the vessel wall or the time it takes for emitted light to travel between the target tissue and back to the lens, producing an "echo time delay" with a measurable signal intensity or "magnitude." Multiple axial scans (A-lines) are continuously
acquired as the imagewire rotates and a full revolution creates a complete cross section of the vessel.

It is important to note that the speed of light $\left(3 \times 10^{8}\right.$ $\mathrm{m} / \mathrm{s})$ is much faster than that of sound $(1,500 \mathrm{~m} / \mathrm{s})$, and, therefore, interferometry techniques are necessary to measure the backscattered signal since a direct quantification cannot be achieved on such a time scale. The interferometer uses a fiberoptic coupler similar to a beam splitter, which directs one-half of the beam to the tissue and the other one-half to the reference arm. The reference arm of a time-domain optical coherence tomography (TD-OCT) system consists of a mirror moving at calibrated distances to produce known echo delays. The reflected signal returning from the tissue and reference arms are recombined in the fiber-coupler, and their interference fringes are detected by a photodetector. The general scheme of an intravascular OCT system is shown in Figure 1.

The axial resolution, determined by the light wavelength, ranges from 12 to 18

Abbreviations and Acronyms

A-line = axial line (scan)
FD-OCT = frequency or Fourier-domain optical coherence tomography

IEL/EEL = internal elastic lamina/external elastic lamina

IVUS = intravascular ultrasound

NIH = neointimal hyperplasia
OCT = optical coherence
tomography
TD-OCT = time-domain
optical coherence
tomography $\mu \mathrm{m}$, compared with 150 to 200 $\mu \mathrm{m}$ for IVUS. The lateral resolution and depth of focus are decoupled from the axial resolution and defined by the spot size focused by the lens in the sample arm. The lateral resolution in catheter-based OCT is typically 20 to $90 \mu \mathrm{~m}$ as compared with 150 to $300 \mu \mathrm{~m}$ for IVUS. For faster image acquisition, the ideal choice is to accelerate the acquisition time of each A-line. This process generates faster cross-sectional imaging, in turn resulting in a higher number of frames per second, which ultimately yields a faster pullback. However, further improvement in speed for time-domain OCT systems is physically limited by generating a fast optical delay in the reference arm and the tradeoff between the imaging speed and sensitivity. Newergenerations of intravascular OCT systems circumvent this limitation by using a fixed mirror with a variable frequency light source or "swept-laser." This method, termed frequency or Fourier-domain optical coherence tomography (FD-OCT), allows the simultaneous detection of reflections from all echo time delays, making the system significantly faster (2). There are 2 types of FD-OCT systems that differ in their method of data extraction from the interferometer: optical frequency domain imaging also known as swept-source OCT, or a spectral domain OCT. The specific features of each system of transformation are outside the scope of this article. A diagram of the main components of the

TD-OCT and FD-OCT systems are shown in Figure 1 and their features contrasted in Table 1.

## Commercial OCT Systems

The first commercially available OCT system was the LightLab M2 TD-OCT Imaging System (LightLab, Westford, Massachusetts). Recently an FD-OCT system (C7 XR, LightLab) has become commercially available in the European Union, Asia, and South America. In the M2/M3 systems, images are recorded by an ImageWire (LightLab), a general purpose, single-mode, fiberoptic wire that rotates inside a fluid-filled polymer tube. A micro lens assembly at the distal end is $\sim 1 \mathrm{~mm}$ in length and $125 \mu \mathrm{~m}$ in diameter (similar to the fiber itself). This assembly focuses and reflects the light beam at $\sim 80^{\circ}$ from the fiber's axis to allow circumferential imaging of the vessel. The wire is attached to an automated pullback engine integrated with the console. The external diameter of the imagewire is 0.019 inches and is fused to a short segment of a standard 0.014-inch guidewire at the distal end. An over-the-wire low-pressure occlusion balloon catheter (Helios, Goodman, Nagoya, Japan) with distal flush ports is used to infuse saline or Ringer's Lactate at approximately $0.5 \mathrm{ml} / \mathrm{s}$ to selectively displace blood during imaging acquisition. Blood must be completely removed, as any amount of residual red blood cells causes significant signal attenuation. Because of safety concerns, the occlusion time is limited by the manufacturer to 30 s . Similar balloon occlusion techniques are used with angioscopy. The new FD-OCT systems can acquire 100 frames/s, reaching pullback speeds up to $20 \mathrm{~mm} / \mathrm{s}$ with the potential to scan 4 - to $6-\mathrm{cm}$ length epicardial coronary vessels in $<5$ s $(3,4)$. Accelerated pullback speeds permit the use of a single, high rate ( $\sim 4 \mathrm{cc} / \mathrm{s}$ ) bolus injection of contrast to produce a blood-free environment, thereby eliminating the need for balloon occlusion $(3,4)$ (Table 1). The Lightlab FD-OCT system is equipped with a tunable laser light source with sweep range of 1,250 to $1,370 \mathrm{~nm}$. The optical fiber is encapsulated within a rotating torque wire built in a rapid exchange $2.6-\mathrm{F}$ catheter compatible with $6-\mathrm{F}$ guides. This system has been already tested in humans in Europe and Japan, and is currently under Food and Drug Administration evaluation. Terumo (Terumo Corporation, Tokyo, Japan) is developing an FD-OCT system, which has a $2.4-\mathrm{F}$ shaft. Volcano (Volcano Corporation, Rancho Cordova, California) is the third FD-OCT system under development with a rapid-exchange nitinol hybrid drive shaft (5).

## OCT Imaging Acquisition Technique

Despite its guidewire-like profile, the OCT ImageWire (Lightlab TD-OCT) is not designed to be advanced into


Figure 1. Scheme of TD-OCT and FD-OCT
A schematic representation of time-domain optical coherence tomography (TD-OCT, left panel) and frequency or Fourier-domain optical coherence tomography (FD-OCT, right panel depicts a subtype of FD-OCT called optical frequency domain imaging [OFDI OCT]). Both systems use a reference arm and an interferometer to detect echo time delays of light. The interferometer uses a beamsplitter, dividing the light into a measurement arm (tissue sample) and a reference arm. The reference arm in TD-OCT is mechanically scanned (by a moving mirror) in order to produce a time-varying time delay. In the FD-OCT, because the light source is frequency swept, the interference of the 2 light beams (tissue and reference) oscillates according to the frequency difference. In both systems the interference of the signal ultimately provides amplitude and frequency data. In the FD-OCT system, all echo delays are acquired simultaneously enabling significant increases in the speed of image acquisition.
the coronary artery as a stand-alone device. Rather, the imagewire is inserted using an over-the-wire balloon catheter (Helios). The Helios balloon has a maximum external diameter of 1.5 mm and is compatible with large 6 -F guiding catheters ( 0.071 -inch inner diameter). It is advanced distally to the segment of interest over a conventional angioplasty guidewire (0.014-inch). The guidewire is then exchanged with the OCT ImageWire, and the occlusion balloon is pulled back and repositioned in a healthy proximal segment. The balloon is highly compliant and is inflated at minimal pressure that allows totally clean imaging from blood, usually between 0.4 to 0.7 atm with a dedicated inflator. A contrast injector pump with a warming cuff is set at $0.5 \mathrm{cc} / \mathrm{s}$ infusion,

| Specifications | TD-OCT | FD-OCT |
| :---: | :---: | :---: |
| Axial scans/s | 5,000-10,000 | $\sim 100,000$ |
| Lines/frame | $\sim 200$ | ~500-1,000 |
| Max. frame rate, fps | 20 | $\sim 200$ |
| Max. pullback speed, mm/s | 3 | 20 |
| Scan diameter (FOV), mm | 6.8 | ~6-11 |
| Axial resolution, $\mu \mathrm{m}$ | 15 | 10-15 |
| Lateral resolution, $\mu \mathrm{m}$ | 90 | 20-40 |
| Tissue penetration, mm | 1.5-3 | 2-3.5 |
| Balloon occlusion | Highly recommended | Optional |
| Catheter size, mm | 0.48 | 0.8-1.0 |
| *Values are approximate; TD-OCT specifications refer to the Lightlab time-domain optical coherence tomography (TD-OCT) system (M2/M3). <br> FD-OCT $=$ frequency or Fourier-domain optical coherence tomography; FOV $=$ field of view; TD-OCT $=$ time-domain optical coherence tomography. |  |  |

which can be increased to up to $1.0 \mathrm{cc} / \mathrm{s}$ until blood is completely cleared. The solution is injected through the end-hole distal port of the occlusion balloon catheter and should start several seconds before balloon occlusion. The pullback speed can be adjusted from 0.5 to $3.0 \mathrm{~mm} / \mathrm{s}$, and the entire imagewire is pulled from distal to proximal along the coronary artery. In the next-generation FDOCT systems, imaging can be performed without balloon occlusion. The pullback speed can reach up to 20 to 40 $\mathrm{mm} / \mathrm{s}$ and is performed during contrast injection ( $\sim 4$ $\mathrm{cc} / \mathrm{s}$ ) to assure complete blood clearance. Imaging of 4 to 6 cm of coronary artery segments can be achieved with $<15$ cc of contrast per pullback. For nonocclusion techniques, iodinated contrast media is preferred over saline or Ringer's lactate because of the advantage of high viscosity solutions in completely removing blood.

Operators should be aware of the vessel size range suitable for OCT imaging, particularly with the first generation devices, ideally between 2.0 to 3.75 mm in diameter. The upper limit is restricted by the scan diameter (field of view) and fold-over artifact (specific to FD-OCT systems), addressed later. In fact, "out-of-screen" loss of image represents the most common technical exclusion of frame analysis in the clinical trials examined in our core laboratory. The field of view was significantly enlarged in the new FD-OCT system (Table 1). The need for a proximally placed balloon in conventional TD-OCT imaging limits its ability to evaluate ostial and highly proximal disease in the coronary arteries since inflation of the Helios balloon in an unprotected left main or diseased segment should not be performed. Other potential sources of image distortion

include excessive vessel tortuosity and the presence of exuberant collateral flow. Studies comparing OCT versus IVUS suggest that TD-OCT is safe and can be performed with success rates at least comparable with IVUS (6-8). Some transient events, such as chest discomfort and ST-T changes, were observed during imaging procedures with OCT or IVUS. Neither hemodynamic instability nor ventricular tachyarrhythmia was observed (7). The feasibility and safety of the larger catheter-based FD-OCT systems remains to be established in future trials.
Pitfalls in imaging post-processing and interpretation Z-offset. Imagewires have minute differences in their optic path lengths. The Z -offset is a manually adjustable image calibration, which is critical for accurate measurements. In the current LightLabs TD-OCT system, the catheter diameter acts as a reference for optimal Z-offset determination within an image frame. The 4 marks or fiduciaries should align to fit the outer surface of the catheter. If the catheter is not well visualized, calibration is performed in a frame where the catheter is in contact with the vascular surface by adjusting the fiduciaries to align the vessel wall. The operator should monitor these patterns throughout the
entire pullback since additional adjustments may be necessary. The majority of corrections are typically made in the first 10 mm of the pullback image. In next-generation FD-OCT catheters, a semitransparent catheter around the optic fiber is more suitable for direct calibration. We have observed that a $1 \%$ change in the magnitude of the ideal Z-offset can result in a $12 \%$ to $14 \%$ error in area measurements. Small changes in magnitude can also amplify contour distortion, which may result in misinterpretation of the image.
Artifacts. Some OCT artifacts are common to both OCT and IVUS, and others are unique to OCT imaging systems. Most of these artifacts will not substantially compromise clinical interpretation of the image, if restricted to few noncontinuous frames, but may render imprecise assessment of plaque characteristics or measurements (Fig. 2).

1. Residual blood attenuates the OCT light beam and may defocus the beam if red cell density is high. This will reduce brightness of the vessel wall, especially at large radial distances from the ImageWire. If the lumen surface is still clearly defined, the presence of diluted


Figure 3. Malapposition Quantification
Cross-section image illustrating various levels of stent strut protrusion. Strut located at 7 o'clock is malapposed (detail). Malapposition is defined when the measured distance from the surface of the blooming to the lumen contour is higher than the total thickness of the stent strut + polymer + one-half of the blooming (the stent surface should be, theoretically, located at one-half the distance of the blooming thickness). In this particular case of a Taxus Express (Boston Scientific, Natick, Massachusetts) stent, the total, estimated, strut thickness $=164 \mu \mathrm{~m}$ (strut thickness $=132 \mu \mathrm{~m}+$ polymer $=16 \mu \mathrm{~m}+$ one-half of the blooming $=18 \mu \mathrm{~m}$ ). The measured distance was $200 \mu \mathrm{~m}$ confirming a malapposed strut. Because of the eccentric wire position, the blooming component is elongated on the struts distant from the wire ( 5 and 7 o'clock), "merry-go-round" effect.
blood does not appear to affect area measurements. Care should be taken to avoid mistakenly labeling residual blood artifact as thrombus or some other specific intravascular finding.
2. Nonuniform rotational distortion is the result of variation in the rotational speed of the spinning optical fiber. It is usually produced by vessel tortuosity or by an imperfection in the torque wire or sheath interfering with smooth rotation of the optical fiber, which can result in focal image loss or shape distortion. Fortunately, this seems to occur less frequently than in IVUS imaging, perhaps as a result of the smaller profile and simplified rotational mechanics of OCT wires.
3. Sew-up artifact is the result of rapid artery or imaging wire movement in 1 frame's imaging formation, leading to single point misalignment of the lumen border.
4. Saturation artifact occurs when light reflected from a highly specular surface (usually stent struts) produces signals with amplitudes that exceed the dynamic range of the data acquisition system (Fig. 2). This should be kept in mind when defining the stent surface. We measured the average "normal" blooming of a stainless steel stent from 2,250 struts in 471 cross-sectional OCT images. The mean measured thickness was $37 \pm$ $8 \mu \mathrm{~m}$ (9). These values are important particularly for
malapposition quantification since the blooming thickness value needs to be considered in addition to stent and polymer thickness.
5. Fold-over artifact is more specific to the new generation of FD-OCT. It is the consequence of the "phase wrapping" or "alias" along the Fourier transformation when structure signals are reflected from outside the system's field of view. Typical examples are side branch and large vessels.
6. Bubble artifact occurs when small gas bubbles are formed in the silicon lubricant used to reduce friction between the sheath and the revolving optic fiber in TD-OCT systems. It can attenuate the signal along a region of the vessel wall, and images with this artifact are not suitable for tissue characterization.
7. Artifacts related to eccentric wire position. Eccentricity of the imagewire in the vessel lumen can influence many aspects of the image interpretation. This phenomenon is likely secondary to imaging sweep speed, and is more pronounced with an eccentric imagewire position, leading to longer distance between each A-line and consequently decreasing the lateral resolution, and has been dubbed the "merry-go-round" effect (Fig. 3). A byproduct of rotational scanning, the reflection from metallic stent struts align toward the imaging wire, akin to sunflowers aligning to the sun or a "sunflower" effect. This effect is pronounced with
eccentric wire position, as it can display strut reflections almost perpendicular to the lumen surface in oblique regions from the wire. This may have important future implications in the serial assessment of strut length, particularly when evaluating the degradation of bioabsorbable stents.

## Clinical Applications

Diagnostic assessment of coronary atherosclerosis. Acknowledging the lack of prospective studies and appropriate animal models to define vulnerable plaque (i.e., ruptureprone), our current understanding of plaque biology suggests that $\sim 80 \%$ of clinically evident plaque rupture originates within an inflamed thin-capped fibroatheroma (10). Plaques containing calcium nodules are associated with $\sim 10 \%$ of clinical events, and plaque that does not fall into either category is associated with $\sim 20 \%$ of clinical atherothrombosis. Superficial plaque erosion may comprise a portion of these events, especially in women and diabetic patients. Because plaque erosion does not have a typical
cellular or anatomical signature, it is currently difficult to prospectively identify those plaques at risk by existing imaging methods. Clinical plaque erosion has been reported by OCT in a similar frequency to pathologic studies $(11,12)$.

Thin-capped fibroatheromas are characterized by 3 essential components: a lipid core, inflammatory cell cap infiltration, and a thin fibrous cap. While OCT does not currently have the depth to quantify large lipid cores, its high resolution allows precise visualization and quantification of the thin fibrous cap $(11,13)$.
FIBROUS CAP. While seminal post-mortem investigations have suggested that a cap thickness $<65 \mu \mathrm{~m}$ (14) is associated with plaque rupture, OCT has demonstrated that patterns of plaque rupture and fibrous cap thickness vary widely. Illustrating this heterogeneity, OCT showed $93 \%$ of the culprit plaques in patients presenting with acute myocardial infarction triggered by exertion had rupture at the shoulder, where the average cap thickness was $90 \mu \mathrm{~m}$. In contrast, $57 \%$ of acute myocardial infarction patients who experienced symptoms at rest had plaque rupture in the shoulder with an average cap thickness of $50 \mu \mathrm{~m}$ (15). OCT

provides the potential for fibrous cap plaque measurement (Fig. 4) and was recently used to demonstrate a significant increase in cap thickness in patients taking a statin versus a control group (16).
inflammation. The large size of macrophages and their high lipid content yield strong optical signals (17-19). Clusters of macrophages can appear as bright spots along the fibrous cap. However, data supporting OCT's capability to quantify macrophages used raw (linear) OCT data from early generation systems (18). The accuracy and validation of current clinical OCT systems for the evaluation of macrophages remains to be demonstrated.
LIPID necrotic core. The lipid/fibrous tissue interface causes a surrounding border of high superficial backscattering. However, light does not penetrate deeply into the necrotic core, and is further absorbed by the lipid tissue providing a subsequent region of low or no signal casting the vascular wall beyond in shadow. This makes the extent of the lipid pool or vascular remodeling difficult to quantify.
calcium nodules. In contrast to ultrasound, light penetrates calcium and OCT depicts calcium with well-defined boundaries (Fig. 5). One OCT study has reported a sensitivity of $96 \%$ and specificity of $97 \%$ to detect calcified nodules (13).
thrombus. Previous studies have suggested that it is possible to identify thrombus by OCT and even discriminate between red and white thrombus, as confirmed by histopathologic correlation (20) (Table 2). The sensitivity of OCT to detect thrombus appears to possibly be higher than that of ultrasound $(11,21)$, but these studies were conducted in a selected population with a high pre-test probability of thrombus. In our experience of $>500$ detailed OCT coronary stent analyses, the discrimination of thrombus from other potentially abnormal intraluminal images can be ambiguous, particularly when these analyses are blinded. Overall, OCT may possess diagnostic advantages compared with both IVUS and angioscopy in the assessment of culprit lesions. Plaque rupture was identifiable in $73 \%$ of OCT images compared with $40 \%$ and $47 \%$, respectively, for IVUS and angioscopy; moreover, plaque erosion was almost exclusively identified by OCT ( $23 \%$ ) in a cohort of patients with acute myocardial infarction (11). The same study reported thrombus identification in all cases by OCT and angioscopy, but only in $33 \%$ of IVUS images.
OCT-guided coronary intervention. Assessment of lumen geometry remains the cornerstone of intravascular imaging criteria to evaluate disease severity and guide interventional procedures. Minimal lumen area, percentage lumen obstruction, percent neointimal hyperplasia (NIH), stent apposition, stent expansion, minimal stent cross section area, lumen gain, late lumen loss, and restenosis are all based on the evaluation of the lumen-vessel/stent interface (22-30). OCT images provide a clear depiction of the boundaries


Figure 5. Optical Coherence Tomography: Histology Correlation
(A) Fibrotic plaque: characterized by high signal (high backscattering) and low attenuation (deep penetration). (B) Predominantly calcified plaque: calcified regions have a sharp border, low signal, and low attenuation permitting deeper penetration. (C) Lipid-rich plaque: the lipid core has a diffuse border. High light attenuation results in poor tissue penetration (in contrast to calcified regions). The overlying fibrotic cap can be readily measured; in this case a thick cap $(>200 \mu \mathrm{~m})$ is present. \#Calcified region; *lipid core. Courtesy of LightLab Imaging (C. Y. Xu and J. M. Schmitt).
between lumen and vessel. OCT's ability to penetrate and delineate calcium in the vessel wall makes it well suited to guide complex interventional strategies in vessels with superficial calcification (Fig. 6D). It is important to note that IVUS-guided vessel dimensions and criteria for percutaneous coronary intervention may vary between different imaging modalities or even different quantification software (31).
We and others have demonstrated the higher sensitivity of OCT compared with IVUS for malapposed strut assessment $(32,33)$. Plaque protrusion and stent-edge dissection are other common intervention-related parameters readily visible on OCT images, although their clinical impact remains to be assessed.


## Research Applications of Intravascular OCT

End point for clinical trials. Stent-strut coverage and apposition have been linked to the risk of stent thrombosis $(34,35)$, and recent DES clinical trials, such as the ODESSA (OCT for DES SAfety) study, have selected these variables as their primary end point (36). Histologic studies have revealed that IVUS does not have adequate resolution to detect the thinnest layers of tissue coverage (37), and the perception that lack of NIH by IVUS is synonymous to an uncovered strut needs to be reconsidered. In a sub-analysis of the ODESSA trial, we identified 20 of

250 stented segments with no detectable NIH by IVUS, but had neointimal coverage ranging from $67 \%$ to $100 \%$ by OCT (38). In contrast to the relatively homogenous lack of NIH detected by IVUS, OCT revealed a highly heterogeneous response to DES, which varied even within the same cross-sectional image.
Strut-level analysis. Our current method of strut-level analysis stratifies struts into 4 main categories: coveredembedded, covered-protruding (into the lumen but covered), uncovered-apposed, and malapposed. A semiautomated stent contour algorithm applies 360 radial chords for detailed quantification of NIH thickness at


Figure 6. Coronary Imaging Acquired With an FD-OCT System
A longitudinal reconstruction (lower panel) and cross-sectional images (upper panels) acquired with a frequency or Fourier-domain optical coherence tomography (FD-OCT) system (Lightlab) at $20 \mathrm{~mm} / \mathrm{s}$ immediately after stent implantation. Note that a $5-\mathrm{cm}$ coronary segment was imaged with a $3-\mathrm{s}$ contrast injection. (A) Distal edge dissection, with corresponding longitudinal view (arrows). (B) Well-expanded and well-apposed stent struts, with corresponding longitudinal view. (C) Malapposed struts between 11 and 1 o'clock, with corresponding longitudinal view (arrows). (D) Proximal calcified plaque with minimal fibrous coverage, with corresponding longitudinal view (arrows).


Figure 7. Quantitative Stent Analysis
(A) Representative frame depicting a Core-Lab area measurement and strut level analysis. Strut level analysis consists of a qualitative assessment for strut coverage and quantitative measurement from the surface of the blooming artifact to the lumen contour. A heterogeneity of strut coverage is observed within a single frame ( $C$ to $N$ refer to labeled struts): covered struts ( $E$ to $G$ ), uncovered apposed struts ( $H$ to J), and malapposed struts ( $K$ to $N, C$ and $D$ ). ( $B$ ) Magnification of the automatic $360^{\circ}$ chord system, applied between the stent and lumen contours, allowing a detailed measurement of the stent coverage. (C) Automatic lumen and stent detection: stent struts (green dots) and lumen contour (red line). (D) En face 3-dimensional view: the highly reflective stent surface allows easy discrimination of the struts from the surrounding tissue. (C and D) LightLab's automated stent strut analysis software (R\&D program, not released) courtesy of LightLab Imaging (C. Y. Xu and J. M. Schmitt), images obtained at Wakayama University (Prof. Akasaka). NIH = neointimal hyperplasia.
every degree of the cross section (Fig. 7). The continuous sampling obtained by OCT also represents an advantage over standard histopathology, which evaluates cross sections in intervals of 2 to 3 mm (39). Taking advantage of such OCT features, one may be able to gather enough information from a relatively small patient cohort to guide drug and device industry before embarking on large population trials.

Our understanding of DES healing in patients with ST-segment elevation myocardial infarction was restricted to post-mortem data (39). A high-rate (49\%) of uncovered struts was observed in previous pathology studies, but the limited number of specimens ( $\mathrm{n}=25$ ) and inherent selection bias of such studies precluded any definitive conclusions. The OCT substudy of the HORIZONS (Harmonizing Outcomes with Revascularization and Stents in AMI) trial (40) evaluated 117 patients (199 stents) in a
prospective, randomized and blinded manner. Stent struts were analyzed at every 0.3 mm at 13 -month post-stenting and revealed a higher percentage of strut coverage in both bare-metal stents and drug-eluting stents ( $98.9 \%$ vs. $94.3 \%$, $\mathrm{p}<0.001$ ) compared with autopsy studies (9).

An important limitation of OCT is the limited precision in discriminating the different kinds of tissue coverage of stents (i.e., endothelium, smooth muscle cells, extracellular matrix). Future studies using histopathologic correlations are needed to define "normal" and "abnormal" stent healing and vessel wall passivation. Importantly, the spatial resolution of current OCT systems is insufficient to detect cell layer thickness $<20 \mu \mathrm{~m}$ on the stent surface, thereby precluding a precise distinction between "true lack of cellular coverage" versus 3 to 5 cell layer coverage of stent struts. On a research basis, OCT is well suited for studying vascular healing over time. In the ongoing OCTAXUS


Figure 8. Comparison Between OCT Capabilities and Others' Imaging Methods
Graphic representation of tissue penetration versus spatial resolution of optical coherence tomography (OCT) compared with other imaging methods. The solid boxes represent the maximal resolution and depth achieved with current technologies. The larger open boxes represent the range of resolution and tissue penetration for each of the technologies. The dashed box illustrates the hypothetical capabilities of future OCT systems. Resolution requirements to accurately detect neointimal hyperplasia observed after drug-eluting stent (NIH) usually exceeds the capabilities of intravascular ultrasound (IVUS). Similarly, fibrous cap thickness can only be assessed in vivo by OCT. However, current OCT systems are not suitable to assess tissue at depths beyond 2 mm . Currently, evaluation of single cell endothelial layers can only be assessed in vitro by microscopy or advance bench-top OCT systems. Atherosclerosis $=$ early and advanced stages of the process; Endothelium = single intimal cell layer; Fibrous Cap $=$ thickness range related to thin cap fibroatheroma.
(OCT Taxus) study, OCT imaging is being performed at 3and 9 -month intervals after stent deployment. Serial studies or observational studies at defined time points may also be helpful in clarifying the role of adjunctive pharmacology in the context of vascular healing (e.g., the intensity and duration of antiplatelet therapy).

## The Future Outlook

The future of OCT will include advancements in anatomical and functional assessment of lesions for the interventional cardiologist.
Anatomical assessment. An advanced edge detection algorithm that enables automated stent strut identification is already available in the research laboratory and is likely to appear in the cathlab in the near future. A similar concept is also being applied to help facilitate tissue characterization (e.g., sharp edges of calcium can be differentiated from diffuse lipid appearance) (Table 2) (Fig. 5). Texture analysis of OCT images may also help facilitate tissue characterization, (e.g., "fractal analysis" uses a computational method of calculating the extent of entropy or randomness found in the tissue image). Polarization takes advantage of the random scattering found in some tissues and reproducible birefringence found in other highly organized tissues (a property of
collagen-rich tissue). Perhaps this may serve as a future index of plaque stability since this organized fibrous tissue seems to be protective. Ultra-bigh resolution OCT, as the name suggests, aims to resolve images to $<10 \mathrm{~m} \mu$. Strategies to accomplish this include ultra-broadband light sources, lower central wavelengths (41), femtosecond lasers (42-45), and multiple superluminescent diodes.
Functional assessment. Contrast enbanced and molecular $O C T$ is an evolving field based on the development and use of nanoparticles, microspheres, and absorbing dyes to increase the local properties of scattering and absorption of light in targeted tissues. Detection of Doppler-like signals using a TD-OCT ImageWire may permit a biophotonic version of the flow wire, thereby allowing integration of physiology and anatomical assessment using a single device.

## Conclusions

OCT enhances imaging resolution (Fig. 8) that may permit the evaluation of clinical (e.g., luminal measurements during PCI ) and research (e.g., fibrous cap thickness and strut level analysis) parameters for the interventional cardiologist. The versatility of the physical properties of light position OCT as an imaging modality could be useful for improving our understanding of the vascular biology of atherothrombosis
and assisting in our performance of PCI procedures. However, routine clinical use of OCT will require further clinical trials to validate the technology, establish standard definitions/measurements, and to test its safety and utility in improving clinical outcomes.

Reprint requests and correspondence: Dr. Marco A. Costa, Division of Cardiology, Heart \& Vascular Institute, University Hospitals, Case Western Reserve University, 11100 Euclid Avenue, Lakeside 3001, Cleveland, Ohio 44106-5038. E-mail: marco.costa@uhhospitals.org.

## REFERENCES

1. Huang D, Swanson EA, Lin CP, et al. Optical coherence tomography. Science 1991;254:1178-81.
2. Chinn SR, Swanson EA, Fujimoto JG. Optical coherence tomography using a frequency-tunable optical source. Opt Lett 1997;22:340-2.
3. Tearney GJ, Waxman S, Shishkov M, et al. Three-dimensional coronary artery microscopy by intracoronary optical frequency domain imaging. J Am Coll Cardiol Img 2008;1:752-61.
4. Barlis P, Schmitt JM. Current and future developments in intracoronary optical coherence tomography imaging. EuroIntervention 2009;4: 529-33.
5. Guagliumi G, Sirbu V. Optical coherence tomography: high resolution intravascular imaging to evaluate vascular healing after coronary stenting. Catheter Cardiovasc Interv 2008;72:237-47.
6. Serruys PW, Ormiston JA, Onuma Y, et al. A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods. Lancet 2009;373:897-910.
7. Yamaguchi T, Terashima M, Akasaka T, et al. Safety and feasibility of an intravascular optical coherence tomography image wire system in the clinical setting. Am J Cardiol 2008;101:562-7.
8. Kubo T, Imanishi T, Kitabata H, et al. Comparison of vascular response after sirolimus-eluting stent implantation between patients with unstable and stable angina pectoris: a serial optical coherence tomography study. J Am Coll Cardiol Img 2008;1:475-84.
9. Guagliumi G, Sirbu V, Costa M, et al. Long-term Strut Coverage of Paclitaxel Eluting Stents Compared to Bare-Metal Stents Implanted During Primary PCI in Acute Myocardial Infarction. A Prospective, Randomized, Controlled Study Performed with Optical Coherence Tomography. HORIZONS-OCT. Paper presented at: Late Breaking Trials, American Heart Association Annual Meeting; November 15, 2008; New Orleans, LA.
10. Schaar JA, Muller JE, Falk E, et al. Terminology for high-risk and vulnerable coronary artery plaques. Report of a meeting on the vulnerable plaque, June 17 and 18, 2003, Santorini, Greece. Eur Heart J 2004;25:1077-82.
11. Kubo T, Imanishi T, Takarada S, et al. Assessment of culprit lesion morphology in acute myocardial infarction: ability of optical coherence tomography compared with intravascular ultrasound and coronary angioscopy. J Am Coll Cardiol 2007;50:933-9.
12. Farb A, Burke AP, Tang AL, et al. Coronary plaque erosion without rupture into a lipid core. A frequent cause of coronary thrombosis in sudden coronary death. Circulation 1996;93:1354-63.
13. Yabushita H, Bouma BE, Houser SL, et al. Characterization of human atherosclerosis by optical coherence tomography. Circulation 2002;106: 1640-5.
14. Burke AP, Farb A, Malcom GT, Liang YH, Smialek J, Virmani R. Coronary risk factors and plaque morphology in men with coronary disease who died suddenly. N Engl J Med 1997;336:1276-82.
15. Tanaka A, Imanishi T, Kitabata H, et al. Distribution and frequency of thin-capped fibroatheromas and ruptured plaques in the entire culprit coronary artery in patients with acute coronary syndrome as determined by optical coherence tomography. Am J Cardiol 2008;102:975-9.
16. Takarada S, Imanishi T, Kubo T, et al. Effect of statin therapy on coronary fibrous-cap thickness in patients with acute coronary syn-
drome: assessment by optical coherence tomography study. Atherosclerosis 2009;202:491-7.
17. MacNeill BD, Jang IK, Bouma BE, et al. Focal and multi-focal plaque macrophage distributions in patients with acute and stable presentations of coronary artery disease. J Am Coll Cardiol 2004;44:972-9.
18. Tearney GJ, Jang IK, Bouma BE. Optical coherence tomography for imaging the vulnerable plaque. J Biomed Opt 2006;11:021002.
19. Raffel OC, Tearney GJ, Gauthier DD, Halpern EF, Bouma BE, Jang IK. Relationship between a systemic inflammatory marker, plaque inflammation, and plaque characteristics determined by intravascular optical coherence tomography. Arterioscler Thromb Vasc Biol 2007; 27:1820-7.
20. Kume T, Akasaka T, Kawamoto T, et al. Assessment of coronary arterial thrombus by optical coherence tomography. Am J Cardiol 2006;97:1713-7.
21. Tanimoto T, Imanishi T, Tanaka A, et al. Various types of plaque disruption in culprit coronary artery visualized by optical coherence tomography in a patient with unstable angina. Circ J 2009;73:187-9.
22. Schiele F, Meneveau N, Vuillemenot A, et al. Impact of intravascular ultrasound guidance in stent deployment on 6-month restenosis rate: a multicenter, randomized study comparing two strategies-with and without intravascular ultrasound guidance. RESIST Study Group. REStenosis after Ivus guided STenting. J Am Coll Cardiol 1998;32: 320-8.
23. Mudra H, di Mario C, de Jaegere P, et al. Randomized comparison of coronary stent implantation under ultrasound or angiographic guidance to reduce stent restenosis (OPTICUS study). Circulation 2001;104: 1343-9.
24. Oemrawsingh PV, Mintz GS, Schalij MJ, Zwinderman AH, Jukema JW, van der Wall EE. Intravascular ultrasound guidance improves angiographic and clinical outcome of stent implantation for long coronary artery stenoses: final results of a randomized comparison with angiographic guidance (TULIP study). Circulation 2003;107:62-7.
25. Serruys PW, Degertekin M, Tanabe K, et al. Intravascular ultrasound findings in the multicenter, randomized, double-blind RAVEL (RAndomized study with the sirolimus-eluting VElocity balloon-expandable stent in the treatment of patients with de novo native coronary artery Lesions) trial. Circulation 2002;106:798-803.
26. Cook S, Wenaweser P, Togni M, et al. Incomplete stent apposition and very late stent thrombosis after drug-eluting stent implantation. Circulation 2007;115:2426-34.
27. Windecker S, Meier B. Late coronary stent thrombosis. Circulation 2007;116:1952-65.
28. Kotani J, Awata M, Nanto S, et al. Incomplete neointimal coverage of sirolimus-eluting stents: angioscopic findings. J Am Coll Cardiol 2006;47:2108-11.
29. Hong MK, Mintz GS, Lee CW, et al. Late stent malapposition after drug-eluting stent implantation: an intravascular ultrasound analysis with long-term follow-up. Circulation 2006;113:414-9.
30. Okabe T, Mintz GS, Buch AN, et al. Intravascular ultrasound parameters associated with stent thrombosis after drug-eluting stent deployment. Am J Cardiol 2007;100:615-20.
31. Hoffmann R, Mintz GS, Popma JJ, et al. Overestimation of acute lumen gain and late lumen loss by quantitative coronary angiography (compared with intravascular ultrasound) in stented lesions. Am J Cardiol 1997;80:1277-81.
32. Bouma BE, Tearney GJ, Yabushita H, et al. Evaluation of intracoronary stenting by intravascular optical coherence tomography. Heart 2003;89:317-20.
33. Rosenthal N, Guagliumi G, Sirbu V, et al. Comparison of intravascular ultrasound and optical coherence tomography for the evaluation of stent segment malapposition (abstr). J Am Coll Cardiol 2009;53 Suppl A:A22.
34. Finn AV, Kolodgie FD, Harnek J, et al. Differential response of delayed healing and persistent inflammation at sites of overlapping sirolimus- or paclitaxel-eluting stents. Circulation 2005;112:270-8.
35. Hassan AK, Bergheanu SC, Stijnen T, et al. Late stent malapposition risk is higher after drug-eluting stent compared with bare-metal stent implantation and associates with late stent thrombosis. Eur Heart J 2009 Jan 21 [E-pub ahead of print].
36. Guagliumi G, Musumeci G, Sirbu V, et al. A Prospective, Randomized, Controlled Study Using Optical Coherence Tomography to Evaluate Strut Coverage of Sirolimus-, Paclitaxel-, and ZotarolimusEluting Coronary Stents in Long Lesions Requiring Overlapping. Paper presented at: Late Breaking Trials, Transcatheter Cardiovascular Therapeutics Annual Meeting; October 14, 2008; Washington, DC.
37. Sousa JE, Costa MA, Sousa AG, et al. Two-year angiographic and intravascular ultrasound follow-up after implantation of sirolimuseluting stents in human coronary arteries. Circulation 2003;107: 381-3.
38. Bezerra H, Guagliumi G, Valescchi O, et al. Unraveling the lack of neointimal hyperplasia detected by intravascular ultrasound using optical coherence tomography: lack of spatial resolution or a true biological effect? (abstr). J Am Coll Cardiol 2009;53 Suppl A:90A.
39. Nakazawa G, Finn AV, Joner M, et al. Delayed arterial healing and increased late stent thrombosis at culprit sites after drug-eluting stent placement for acute myocardial infarction patients: an autopsy study. Circulation 2008;118:1138-45.
40. Guagliumi G, Sirbu V, Costa M, da Costa CA. Long-term strut coverage of paclitaxel eluting stents compared with bare-metal stents implanted during primary PCI in acute myocardial infarction: a
prospective, randomized, controlled study performed with optical coherence tomography. HORIZONS-OCT (abstr). Circulation 2008; 118:2315.
41. Wang H, Fleming CP, Rollins AM. Ultrahigh-resolution optical coherence tomography at 1.15 um using photonic crystal fiber with no zero-dispersion wavelengths. Opt Express 2007;15:3085-92.
42. Hartl I, Li XD, Chudoba C, et al. Ultrahigh-resolution optical coherence tomography using continuum generation in an air silica microstructure optical fiber. Opt Lett 2001;26:608-10.
43. Herz P, Chen Y, Aguirre A, et al. Ultrahigh resolution optical biopsy with endoscopic optical coherence tomography. Opt Express 2004;12: 3532-42.
44. Drexler W. Ultrahigh-resolution optical coherence tomography. J Biomed Opt 2004;9:47.
45. Wang H, Jenkins MW, Rollins AM. A combined multiple-SLED broadband light source at 1300 nm for high resolution optical coherence tomography. Opt Commun 2008;281:1896-900.

Key Words: optical coherence tomography coronary stent $\square$ atherosclerosis.

# Intracoronary Optical Coherence Tomography: A Comprehensive Review: Clinical and Research Applications <br> Hiram G. Bezerra, Marco A. Costa, Giulio Guagliumi, Andrew M. Rollins, and Daniel I. Simon <br> J. Am. Coll. Cardiol. Intv. 2009;2;1035-1046 <br> doi:10.1016/j.jcin.2009.06.019 

This information is current as of August 9, 2010

| Updated Information <br> \& Services | including high-resolution figures, can be found at: <br> Supplementary Material <br> http://interventions.onlinejacc.org/cgi/content/full/2/11/1035 |
| :--- | :--- |
|  | Supplementary material can be found at: <br> http://interventions.onlinejacc.org/cgi/content/full/2/11/1035/ <br> DC1 |
|  | This article cites 42 articles, 23 of which you can access for <br> free at: <br> http://interventions.onlinejacc.org/cgi/content/full/2/11/1035\# <br> BIBL |
|  | This article has been cited by 1 HighWire-hosted articles: <br> http://interventions.onlinejacc.org/cgi/content/full/2/11/1035\# <br> otherarticles |
| Rights \& Permissions | Information about reproducing this article in parts (figures, <br> tables) or in its entirety can be found online at: <br> http://interventions.onlinejacc.org/misc/permissions.dtl |
|  | Information about ordering reprints can be found online: |
|  | http://interventions.onlinejacc.org/misc/reprints.dtl |
|  |  |




[^0]:    From the *Harrington-McLaughlin Heart \& Vascular Institute, University Hospitals Case Medical Center, and the $\dagger$ Department of Biomedical Engineering, Case Western Reserve University School of Medicine, Cleveland, Ohio; and the $\ddagger$ Cardiovascular Department Ospedali Riuniti di Bergamo, Bergamo, Italy. Dr. Bezerra received research grants and consulting honoraria from Lightlab. Dr. Costa received research grants and consulting honoraria from Lightlab and Cordis/Johnson \& Johnson. Dr. Guagliumi received research grants from Medtronic Vascular, Lightlab, and Boston Scientific. Dr. Simon received research grants from Medtronic Vascular and Cordis/Johnson \& Johnson.
    Manuscript received May 15, 2009; revised manuscript received June 16, 2009, accepted June 25, 2009.

